|Bid||0.2200 x 0|
|Ask||0.4500 x 0|
|Day's Range||0.3600 - 0.4500|
|52 Week Range||0.3600 - 2.9900|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details
A look at the shareholders of Nuvo Pharmaceuticals Inc. (TSE:NRI) can tell us which group is most powerful. Insiders...
Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference
MISSISSAUGA, ON , July 31, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio ...
OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided an update regarding its VIMOVO patents. The Company has received notice that the United States Court of Appeals (the Court of Appeals) has denied the Company's request to rehear Nuvo's case with respect to the validity of patents 6,926,907 and 8,557,285 (the '907 and '285 Patents) covering speciality pain medicine VIMOVO.
Nuvo Pharmaceuticals Inc. (TSE:NRI) shareholders should be happy to see the share price up 13% in the last month. But...
OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2019 Annual Meeting of Shareholders held on June 25, 2019 in Mississauga , all nominees listed in the management proxy circular dated May 16, 2019 were elected as directors of the Company. "On behalf of the Company and the entire Board of Directors, I want to thank Dr. Jacques Messier , our outgoing director, for his contributions to the Board over the past 15 years," commented Rob Harris , Nuvo's Executive Chairman.
OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided a corporate update on various matters including its VIMOVO patents, the identification of Aralez Transaction synergies and an update regarding the status of its financing arrangements with Deerfield Management Company, L.P. ( Deerfield ). The Company continues to assess its options, including legal challenges, to seek to overturn a recent decision by the United States Court of Appeals that invalidated United States ("U.S.") patents 6,926,907 and 8,557,285 covering VIMOVO ("the '907 and '285 Patents"), reversing a previous ruling by the United States District Court that validated the '907 and '285 patents.
OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United States Court of Appeals for the Federal Circuit reversed the decision by the United States District Court for the District of New Jersey related to certain Vimovo patents. This ruling reverses the decision made on July 10, 2017 involving patents U.S. Patent Nos.
On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 49 cents. Losses, adjusted for non-recurring costs, were 15 cents per share. The drugmaker posted revenue of $10.9 million ...